ELVIS ELEM Virtual Heart Populations for Supercomputers
- Coordinator
- Elem Biotech SL, Spain
- Runs
- 1 March 2023 to 31 August 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190134524
What the project is doing
In the project's own words, from its summary on CORDIS.
ELEMs V.Heart is a supercomputer-based platform to perform massive in-silico clinical trials on populations of digital avatars generated through a database of real medical data, to study the outcomes of different therapies. It assesses the safety and efficacy of novel therapeutics, devices or drugs, by computing thousands of scenarios. Current capability covers classic or leadless pacing and cardiac pumps and cardiac safety of drugs.
Our plan is to add new therapies whilst increasing the range of our patented virtual population technology. V.Heart generates unparalleled medical insights and new evidence for biomedical professionals whilst shortening time to market and reducing business and patient risks. It narrows the scope for animal testing and tapers real human trials by evaluating clinical study endpoints much faster and earlier in the development process.
Eventually, digital avatars become a Digital Twin of any given patient used as a predictive tool for precision medicine.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Elem Biotech SL | Barcelona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI